CR20190150A - Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad, kits, y métodos - Google Patents
Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad, kits, y métodosInfo
- Publication number
- CR20190150A CR20190150A CR20190150A CR20190150A CR20190150A CR 20190150 A CR20190150 A CR 20190150A CR 20190150 A CR20190150 A CR 20190150A CR 20190150 A CR20190150 A CR 20190150A CR 20190150 A CR20190150 A CR 20190150A
- Authority
- CR
- Costa Rica
- Prior art keywords
- formulations
- kits
- masp
- low viscosity
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a formulaciones de anticuerpos inhibidores de MASP-2 estables, de alta concentración y de baja viscosidad, a kits que comprenden las formulaciones y a métodos terapéuticos que usan las formulaciones y a kits para inhibir los efectos adversos de la activación del complemento dependiente de MASP-2The present invention relates to stable, high-concentration low-viscosity formulations of MASP-2 inhibitory antibodies, kits comprising the formulations and therapeutic methods using the formulations and kits for inhibiting the adverse effects of MASP-2 dependent complement activation.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662382156P | 2016-08-31 | 2016-08-31 | |
| PCT/US2017/049415 WO2018045054A1 (en) | 2016-08-31 | 2017-08-30 | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20190150A true CR20190150A (es) | 2019-05-14 |
Family
ID=61301617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20190150A CR20190150A (es) | 2016-08-31 | 2017-08-30 | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad, kits, y métodos |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US11628217B2 (es) |
| EP (2) | EP3506886B1 (es) |
| JP (2) | JP6864747B2 (es) |
| KR (2) | KR102444154B1 (es) |
| CN (3) | CN109890367B (es) |
| AR (1) | AR109494A1 (es) |
| AU (2) | AU2017321605B2 (es) |
| CA (1) | CA3035252C (es) |
| CL (1) | CL2019000508A1 (es) |
| CO (1) | CO2019002239A2 (es) |
| CR (1) | CR20190150A (es) |
| CU (1) | CU20190015A7 (es) |
| DK (1) | DK3506886T3 (es) |
| EA (1) | EA201990598A1 (es) |
| EC (1) | ECSP19021312A (es) |
| ES (1) | ES2986902T3 (es) |
| FI (1) | FI3506886T3 (es) |
| GE (1) | GEP20217252B (es) |
| HR (1) | HRP20241131T1 (es) |
| HU (1) | HUE068084T2 (es) |
| IL (1) | IL265071B2 (es) |
| JO (1) | JOP20170170B1 (es) |
| LT (1) | LT3506886T (es) |
| MA (1) | MA46109A (es) |
| MX (2) | MX2019002338A (es) |
| MY (1) | MY189411A (es) |
| PE (1) | PE20190469A1 (es) |
| PH (1) | PH12019500365A1 (es) |
| PL (1) | PL3506886T3 (es) |
| PT (1) | PT3506886T (es) |
| PY (1) | PY1763675A (es) |
| RS (1) | RS65845B1 (es) |
| SG (2) | SG11201901444PA (es) |
| SI (1) | SI3506886T1 (es) |
| SM (1) | SMT202400333T1 (es) |
| TW (2) | TWI719245B (es) |
| UA (1) | UA122733C2 (es) |
| UY (1) | UY37391A (es) |
| WO (1) | WO2018045054A1 (es) |
| ZA (1) | ZA201901891B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3185172A1 (en) * | 2016-01-05 | 2017-07-13 | Omeros Corporation | Methods for inhibiting fibrosis in a subject in need thereof |
| JOP20170170B1 (ar) * | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
| JOP20190068A1 (ar) * | 2016-10-13 | 2019-04-01 | Omeros Corp | طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي |
| AU2018322032B2 (en) * | 2017-08-25 | 2025-04-17 | Omeros Corporation | Highly concentrated low viscosity MASP-2 inhibitory antibody formulations, kits, and methods of treating subjects suffering from atypical hemolytic syndrome |
| US20230182041A1 (en) * | 2018-04-25 | 2023-06-15 | Medimmune, Llc | Purification of antibodies |
| WO2019231935A1 (en) | 2018-05-29 | 2019-12-05 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| EP4559485A3 (en) | 2018-07-19 | 2025-08-06 | Ichnos Sciences S.A. | Liquid antibody formulation |
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| EP3999537A1 (en) * | 2019-07-19 | 2022-05-25 | Ichnos Sciences SA | Lyophilized antibody formulation |
| EP4065165A4 (en) * | 2019-11-26 | 2024-10-16 | Omeros Corporation | METHODS FOR TREATING AND/OR PREVENTING IDIOPATHIC PNEUMONIA SYNDROME (IPS) AND/OR CAPILLARY LEAK SYNDROME (CLS) AND/OR ENGRAFTMENT SYNDROME (ES) AND/OR FLUID OVERLOAD (FO) ASSOCIATED WITH HEMATOPOETIC STEM CELL TRANSPLANTATION |
| CA3159172A1 (en) | 2019-12-04 | 2021-06-10 | Michael Cicirelli | Masp-2 inhibitors and methods of use |
| EP4069676A1 (en) | 2019-12-04 | 2022-10-12 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| AU2020397894B2 (en) | 2019-12-04 | 2025-02-20 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| EP4069238A1 (en) | 2019-12-04 | 2022-10-12 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| CA3190474A1 (en) | 2020-07-31 | 2022-02-03 | Alamab Therapeutics, Inc. | Anti-connexin antibody formulations |
| CN116615182A (zh) * | 2020-10-22 | 2023-08-18 | 爱乐科斯公司 | 抗siglec-8抗体制剂 |
| BR112023025596A2 (pt) * | 2021-06-08 | 2024-02-27 | Jiangxi Jemincare Group Co Ltd | Anticorpo anti-masp-2 e uso do mesmo |
| PY22106817A (es) | 2021-12-10 | 2023-12-21 | Omeros Corp | Anticuerpos terapéuticos que se unen al dominio serina-proteasa de masp-2 y usos de estos |
| EP4489782A4 (en) * | 2022-03-10 | 2026-03-25 | Omeros Corp | MASP-2 and MASP-3 inhibitors, and associated compositions and methods for the treatment of sickle cell disease |
| JP2025541737A (ja) | 2022-11-30 | 2025-12-23 | オメロス コーポレーション | Ｍａｓｐ－２阻害物質としての縮合ピリミジン |
| CN120475992A (zh) * | 2022-12-29 | 2025-08-12 | 苏州创胜医药集团有限公司 | 含有治疗性抗体的药物制剂及其用途 |
| WO2024226573A2 (en) * | 2023-04-25 | 2024-10-31 | Nuvance Health | Masp-2 directed cancer treatment methods |
| US12216123B2 (en) | 2023-04-25 | 2025-02-04 | Nuvance Health | Extracellular vesicle derived MASP-2 directed cancer treatment methods |
| CN116712390B (zh) * | 2023-08-04 | 2023-11-14 | 上海览屹医药科技有限公司 | 一种高浓度高稳定性的抗体制剂及其制备方法 |
| WO2025054172A1 (en) * | 2023-09-05 | 2025-03-13 | E-Star Biotech, LLC | Formulations of manp and uses thereof |
| US20250122225A1 (en) | 2023-10-06 | 2025-04-17 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| CN121490076A (zh) * | 2026-01-13 | 2026-02-10 | 上海麦济医药有限公司 | 一种稳定的抗人masp2单克隆抗体制剂 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| CA2634131C (en) | 2005-12-21 | 2014-02-11 | Wyeth | Protein formulations with reduced viscosity and uses thereof |
| BR112012008970A2 (pt) | 2009-10-16 | 2019-12-10 | Omeros Corp | uso de uma composição, e, composição |
| US9072668B2 (en) * | 2010-03-09 | 2015-07-07 | Janssen Biotech, Inc. | Non-aqueous high concentration reduced viscosity suspension formulations of antibodies |
| NZ731596A (en) * | 2011-04-08 | 2022-07-01 | Omeros Corp | Methods for treating conditions associated with masp-2 dependent complement activation |
| US20150166676A1 (en) * | 2011-04-08 | 2015-06-18 | Omeros Corporation | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| TWI907924B (zh) * | 2011-05-02 | 2025-12-11 | 日商武田藥品工業股份有限公司 | 抗-α4β7抗體之調配物 |
| MX347691B (es) | 2011-05-04 | 2017-05-09 | Omeros Corp | Composiciones para inhibir la activacion del complemento dependiente de la masp-2. |
| CN115040653A (zh) * | 2012-06-18 | 2022-09-13 | 奥默罗斯公司 | 抑制masp-1和/或masp-2和/或masp-3的组合物和方法 |
| WO2014141149A1 (en) | 2013-03-15 | 2014-09-18 | Glaxosmithkline Intellectual Property (No.2) Limited | Formulations with reduced viscosity |
| CN105683219B (zh) | 2013-10-17 | 2020-07-14 | 奥默罗斯公司 | 用于治疗与masp-2依赖性补体活化有关的病况的方法 |
| JP2017527560A (ja) * | 2014-09-03 | 2017-09-21 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | 安定抗ｉｌ−４ｒアルファ抗体配合物 |
| EP3240571A4 (en) | 2014-12-31 | 2018-06-13 | NovelMed Therapeutics, Inc. | Formulation of aglycosylated therapeutic antibodies |
| EP3373963A4 (en) | 2015-11-09 | 2019-07-10 | Omeros Corporation | METHODS OF TREATING SUFFERING RELATED TO MASP-2-DEPENDENT COMPLEMENTAL ACTIVATION |
| CA3185172A1 (en) | 2016-01-05 | 2017-07-13 | Omeros Corporation | Methods for inhibiting fibrosis in a subject in need thereof |
| US20170253667A1 (en) | 2016-01-05 | 2017-09-07 | University Of Leicester | Methods for inhibiting fibrosis in a subject in need thereof |
| MX2018011648A (es) | 2016-03-31 | 2019-01-30 | Omeros Corp | Metodos para la inhibicion de fibrosis en un sujeto en necesidad del mismo. |
| JOP20170170B1 (ar) * | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
| TWI834025B (zh) * | 2020-03-06 | 2024-03-01 | 美商奥默羅斯公司 | 用於治療和/或預防冠狀病毒誘導的急性呼吸窘迫症候群的抑制masp-2的方法 |
-
2017
- 2017-08-28 JO JOP/2017/0170A patent/JOP20170170B1/ar active
- 2017-08-29 TW TW106129287A patent/TWI719245B/zh active
- 2017-08-29 TW TW108111015A patent/TWI730310B/zh active
- 2017-08-30 SG SG11201901444PA patent/SG11201901444PA/en unknown
- 2017-08-30 KR KR1020217035424A patent/KR102444154B1/ko active Active
- 2017-08-30 IL IL265071A patent/IL265071B2/en unknown
- 2017-08-30 JP JP2019531596A patent/JP6864747B2/ja active Active
- 2017-08-30 CU CU2019000015A patent/CU20190015A7/es unknown
- 2017-08-30 HU HUE17847485A patent/HUE068084T2/hu unknown
- 2017-08-30 SM SM20240333T patent/SMT202400333T1/it unknown
- 2017-08-30 EA EA201990598A patent/EA201990598A1/ru unknown
- 2017-08-30 RS RS20240925A patent/RS65845B1/sr unknown
- 2017-08-30 CR CR20190150A patent/CR20190150A/es unknown
- 2017-08-30 PL PL17847485.4T patent/PL3506886T3/pl unknown
- 2017-08-30 CN CN201780051640.7A patent/CN109890367B/zh active Active
- 2017-08-30 AU AU2017321605A patent/AU2017321605B2/en active Active
- 2017-08-30 ES ES17847485T patent/ES2986902T3/es active Active
- 2017-08-30 CN CN202210971376.1A patent/CN116327917A/zh active Pending
- 2017-08-30 PT PT178474854T patent/PT3506886T/pt unknown
- 2017-08-30 EP EP17847485.4A patent/EP3506886B1/en active Active
- 2017-08-30 LT LTEPPCT/US2017/049415T patent/LT3506886T/lt unknown
- 2017-08-30 KR KR1020197008678A patent/KR20190043161A/ko not_active Ceased
- 2017-08-30 WO PCT/US2017/049415 patent/WO2018045054A1/en not_active Ceased
- 2017-08-30 CA CA3035252A patent/CA3035252C/en active Active
- 2017-08-30 HR HRP20241131TT patent/HRP20241131T1/hr unknown
- 2017-08-30 FI FIEP17847485.4T patent/FI3506886T3/fi active
- 2017-08-30 MX MX2019002338A patent/MX2019002338A/es unknown
- 2017-08-30 CN CN202210971401.6A patent/CN116327695A/zh active Pending
- 2017-08-30 SI SI201731539T patent/SI3506886T1/sl unknown
- 2017-08-30 MA MA046109A patent/MA46109A/fr unknown
- 2017-08-30 PE PE2019000408A patent/PE20190469A1/es unknown
- 2017-08-30 UA UAA201903034A patent/UA122733C2/uk unknown
- 2017-08-30 EP EP24160975.9A patent/EP4438060A3/en active Pending
- 2017-08-30 MY MYPI2019000424A patent/MY189411A/en unknown
- 2017-08-30 US US15/691,266 patent/US11628217B2/en active Active
- 2017-08-30 GE GEAP201715038A patent/GEP20217252B/en unknown
- 2017-08-30 SG SG10202100697PA patent/SG10202100697PA/en unknown
- 2017-08-30 DK DK17847485.4T patent/DK3506886T3/da active
- 2017-08-31 UY UY0001037391A patent/UY37391A/es active IP Right Grant
- 2017-08-31 AR ARP170102432A patent/AR109494A1/es not_active Application Discontinuation
- 2017-08-31 PY PY201701763675A patent/PY1763675A/es unknown
-
2019
- 2019-02-20 PH PH12019500365A patent/PH12019500365A1/en unknown
- 2019-02-26 MX MX2023014120A patent/MX2023014120A/es unknown
- 2019-02-26 CL CL2019000508A patent/CL2019000508A1/es unknown
- 2019-03-11 CO CONC2019/0002239A patent/CO2019002239A2/es unknown
- 2019-03-27 EC ECSENADI201921312A patent/ECSP19021312A/es unknown
- 2019-03-27 ZA ZA2019/01891A patent/ZA201901891B/en unknown
-
2020
- 2020-11-24 AU AU2020277135A patent/AU2020277135B2/en active Active
-
2021
- 2021-04-02 JP JP2021063245A patent/JP7197623B2/ja active Active
-
2023
- 2023-02-28 US US18/176,155 patent/US20230226178A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20190150A (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad, kits, y métodos | |
| ECSP19015192A (es) | Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos | |
| CL2021001179A1 (es) | Anticuerpos específicos para tl1a y ácidos nucleicos que los codifican (divisional de la solicitud no. 201801596). | |
| CL2020003409A1 (es) | Moléculas de unión específicas para cd73 y métodos de fabricación de las mismas (divisional de la solicitud no. 201701154) | |
| MX2021006154A (es) | Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. | |
| CO2022008662A2 (es) | Degradadores de smarca y usos de los mismos | |
| CL2018001899A1 (es) | Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock) | |
| CL2018003142A1 (es) | Moduladores de la vía de estrés integrada | |
| MX2018008052A (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
| MX2018003898A (es) | Proteínas de unión al antígeno anti-tigit y métodos para usarlas. | |
| CL2018000687A1 (es) | Nuevos compuestos bicíclicos como inhibidores de atx. | |
| MX373341B (es) | INHIBIDORES DE PROTEíNA CINASA 2 ACTIVADA POR PROTEíNA CINASA ACTIVADA POR MITóGENO (MK2) Y SUS USOS. | |
| MX381046B (es) | Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas. | |
| MX2022000053A (es) | Moduladores de interaccion de sestrina-gator2 y sus usos. | |
| MX2019015744A (es) | Composiciones farmaceuticas. | |
| CL2018001252A1 (es) | Métodos para tratar esclerosis múltiple usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton | |
| GT201600250A (es) | Compuestos de 1, 3, 4- tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| CO2020015747A2 (es) | Analogos de rapamicina y usos de los mismos | |
| MX2020001885A (es) | Formulaciones de daptomicina. | |
| CL2017000715A1 (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo | |
| CL2020000397A1 (es) | Formulaciones de anticuerpos inhibitorio para masp-2 de baja viscosidad altamente concentradas, kits, y métodos de tratamiento de sujetos que sufren de síndrome hemolítico atípico. | |
| MX2021011334A (es) | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. | |
| MX2021003888A (es) | Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares. | |
| SV2017005474A (es) | Nuevas formas sólidas de desvenlafaxina |